Our Q1 2026 review reflects a shift toward fewer, larger, higher-quality biopharma R&D partnerships, with stronger upfront capital deployment and sustained deal flow, reinforcing disciplined investment.
Biopharma Therapeutic and Platform R&D Partnerships declined to 112 deals, generating $79.4B versus 129 deals and $81.5B in Q4 2025; upfront increased to $4.9B from $4.1B, with average upfront at $131M (vs $85M) and median at $60M (vs $55M). Combined, 241 deals totaled $160.9B with $8.9B upfront.
Biopharma vs Other Life Sciences and Number of R&D Partnerships led with 73 deals in Q1 2026 (vs 100 in Q4 2025), ahead of Diagnostics and Omics (43) and Manufacturing Tech (16), with Medtech at 0; across both quarters, Therapeutic Platforms and Biopharma dominated with 173 deals versus 79 and 29, respectively.
Biopharma vs Other Life Sciences Total Deal Value in Q1 2026 saw a balanced split with Therapeutic Platforms and Biopharma at $40.6B and Diagnostics and Omics at $39.7B; Q4 2025 was more concentrated (Therapeutic Platforms and Biopharma at $62.6B vs $13.6B and $9.4B). Across both quarters, Biopharma led with $103.2B, while Diagnostics and Omics gained share.
$100M+ Club had 14 deals delivering $49.4B in Q1 2026 (vs 12 deals, $26.2B in Q4 2025), with upfront rising to $4B from $2.6B; average deal value reached $3.5B (vs $2.2B) and average upfront $289M (vs $219M). Combined, 26 deals generated $75.7B with $6.7B upfront.
Deal flow was led by, Eli Lilly & Innovent ($350M upfront; up to $8.5B) highlights large-scale antibody platform partnerships; AbbVie & RemeGen ($650M upfront; up to $5B) reflects late stage oncology focus; Madrigal Pharmaceuticals & Suzhou Ribo ($60M upfront; up to $4.3B) underlines RNA platform expansion; Eli Lilly & Repertoire ($85M upfront; up to $1.8B) signals growing immunotherapy platform bets; and Astellas Pharma & Vir ($240M upfront + $75M equity; up to $1.4B) demonstrates complex, risk-sharing oncology structures with profit splits.
In Q1 2026, biopharma therapeutics and platform R&D partnerships declined in volume but remained robust in value. A total of 112 deals generated $79.4B, slightly below the $81.5B recorded across 129 deals in Q4 2025. Despite 17 fewer transactions, upfront cash and equity increased to $4.9B from $4.1B, indicating greater near-term capital commitment per deal. Deal economics strengthened further, with average upfront value rising to $131M from $85M and median upfront increasing to $60M from $55M. Combined, the two quarters delivered 241 deals totaling $160.9B, including $8.9B in upfront cash and equity.
Biopharma Therapeutics and Platforms vs Other Life Sciences
In Q1 2026, life sciences R&D partnerships declined from Q4 2025, though Therapeutic Platforms and Biopharma remained clear leaders with 73 deals. Diagnostics, Sequencing, Omics, and Tools followed with 43 deals, while Manufacturing Tech and Others recorded 16 deals. Medtech, Devices, Digital Tx, and Wearables saw no partnership activity during the quarter. By comparison, Q4 2025 showed stronger momentum, led by Therapeutic Platforms and Biopharma with 100 deals. Diagnostics and related tools accounted for 36 deals, Manufacturing Tech and Others posted 13, and Medtech recorded just 1 deal. Across both quarters, Therapeutic Platforms and Biopharma dominated with 173 partnerships, outpacing Diagnostics and Omics at 79 and Manufacturing Tech and Others at 29.
In Q1 2026, life sciences R&D partnerships became more evenly distributed across segments. Therapeutic Platforms and Biopharma generated $40.6B, followed by Diagnostics, Sequencing, Omics, and Tools at $39.7B. Manufacturing Tech and Others contributed $4B, while Medtech, Devices, Digital Tx, and Wearables recorded no deal value. In contrast, Q4 2025 was more concentrated, with Therapeutic Platforms and Biopharma leading at $62.6B, well ahead of Diagnostics and related tools at $13.6B and Manufacturing Tech and Others at $9.4B. Medtech again recorded no deal. Across two quarters, Therapeutic Platforms and Biopharma remained the largest segment with $103.2B in total deal value. However, the sharp increase in Diagnostics and Omics activity in Q1 2026 indicates concentration in other high-value life sciences segments.
Â
Biopharma Therapeutics and Platforms R&D Partnerships – $100M+ Club
In Q1 2026, Biopharma Therapeutics and Platforms R&D partnerships in the $100M+ segment strengthened notably, with 14 deals generating $49.4B in total value, up from 12 deals worth $26.2B in Q4 2025. Upfront cash and equity increased to $4B from $2.6B, while average total deal value rose to $3.5B from $2.2B, and average upfront value climbed to $289M from $219M. Across both quarters, the $100M+ segment accounted for 26 deals totaling $75.7B, including $6.7B in upfront cash and equity.
Top Biopharma Therapeutics and Platforms R&D Partnerships in Q1 2026
Innovent development and commercialization deal with Eli Lilly – February 2026
In February 2026 at Platform and Discovery stage, Innovent, through its subsidiaries Innovent Biologics (Suzhou), Fortvita Biologics (Singapore), Fortvita Biologics Inc., and Fortvita Biologics (USA), granted Eli Lilly exclusive worldwide rights outside China to develop and commercialize antibody therapies for cancer and autoimmune indications, while retaining Greater China rights and leading early research and clinical development through Phase II in China using its antibody platforms; Lilly will oversee global development and commercialization, with the deal including $350M upfront, up to $8.5B in development, regulatory, and commercial milestones, and tiered royalties.
RemeGen development and commercialization deal with AbbVie – January 2026
In January 2026 at the Phase II stage, RemeGen granted AbbVie exclusive worldwide rights outside China to develop, manufacture, and commercialize RC148, a PD-1/VEGF bispecific antibody targeting advanced solid tumors, including certain lung cancers, with ongoing evaluation as both a monotherapy and in combination regimens such as with antibody drug conjugates; the agreement includes $650M upfront, up to $5B in development, regulatory, and commercial milestones, and double digit tiered royalties.
Suzhou Ribo Life Science development and commercialization deal with Madrigal Pharmaceuticals – February 2026
In February 2026 at the Preclinical and IND stage, Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals AB granted Madrigal Pharmaceuticals exclusive worldwide rights to develop and commercialize 6 undisclosed siRNA programs for metabolic dysfunction associated steatohepatitis (MASH), leveraging Ribo’s liver targeting GalSTAR platform, with an option to expand into additional bispecific siRNA programs; the agreement includes $60M upfront and up to $4.3B in development and sales milestones, plus undisclosed royalties.
Repertoire Immune Medicines development and commercialization deal with Eli Lilly – January 2026
In January 2026 at the Platform and Discovery stage, Repertoire Immune Medicines granted Eli Lilly rights to develop and commercialize tolerizing therapies for multiple autoimmune diseases using its DECODE platform, which maps T cell receptor epitope interactions, with Repertoire leading early discovery and development and Lilly assuming responsibility for clinical development, manufacturing, regulatory activities, and commercialization; the agreement includes $85M upfront and up to $1.8B in development and commercial milestones, plus tiered royalties.
Vir Biotechnology development and commercialization deal with Astellas – February 2026
In February 2026, at the Phase-I stage, Vir Biotechnology partnered with Astellas Pharma to co-develop and co-commercialize VIR-5500, a CD3 T cell engager targeting PSMA for prostate cancer, with Vir leading Phase I before transitioning development; Astellas funds 60% of global costs (Vir 40%), holds ex-U.S. commercialization rights, and shares U.S. profits with a co-promotion option for Vir. The deal includes $240M upfront, $75M equity at a 50% premium, $20M near-term milestones, and up to $1.4B in milestones, plus double-digit ex-U.S. royalties and an undisclosed U.S. profit split, with proceeds partially shared with Sanofi.
Also check out Biopharma Therapeutics and Platforms IPO, Follow-on, and PIPE Issuances – 2025 Review
